Online citations, reference lists, and bibliographies.
← Back to Search

Pleural Thickness After Neoadjuvant Chemotherapy Is A Prognostic Factor In Malignant Pleural Mesothelioma

M. Hashimoto, Jiro Takeuchi, T. Takuwa, A. Kuroda, Akifumi Nakamura, T. Nakamichi, S. Matsumoto, Nobuyuki Kondo, T. Nakano, T. Morimoto, S. Hasegawa
Published 2019 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Objectives: Definitive diagnosis of the T‐component is sometimes challenging in malignant pleural mesothelioma (MPM). Pleural thickness has been reported to be a prognostic factor for MPM and is a potential T‐component. Methods: We conducted a historical cohort study of patients who underwent neoadjuvant chemotherapy (NAC) and curative‐intent surgery as a multimodal treatment for MPM from January 2007 to June 2016. The maximum measurement of pleural thickness among 3 levels and the sum at each level determined using axial computed tomography imaging before and after NAC were termed as “max” and “sum,” respectively. We assessed the association between pleural thickness and the primary and secondary end points of overall survival and recurrence‐free survival. Survival was analyzed using the Kaplan–Meier curve, log rank test, and multivariate Cox regression model. Results: We enrolled 105 patients. We excluded 1 because of missing data; thus, the sample size was 104. The median follow‐up period was 29.1 months with recurrence in 78 patients (70.3%) and death in 67 (60.4%). Max and sum ranged from pre (before NAC) values of 0 to 35 (median, 6.05) and 0 to 97 (median, 12.9) to post (after NAC) values of 0 to 30.8 (median, 4.25) and 0 to 67.0 (median, 9.25), respectively. Post values max and sum were associated with overall survival and recurrence‐free survival. Post sum values were associated with recurrence (adjusted hazard ratio, 2.59; 95% confidence interval, 1.42‐3.83) and death (adjusted hazard ratio, 2.13; 95% confidence interval, 1.16‐4.52), respectively. Conclusions: Pleural thickness after NAC was an independent prognostic factor in patients who underwent multimodal treatment.
This paper references
A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma.
C. Cao (2014)
Impact of tumour thickness on survival after radical radiation and surgery in malignant pleural mesothelioma
M. D. de Perrot (2017)
Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically.
V. Rusch (1999)
Management of malignant pleural mesothelioma-The European experience.
I. Opitz (2014)
The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma
D. Rice (2016)
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
Three-dimensional evaluation of chemotherapy response in malignant pleural mesothelioma.
G. Ak (2010)
A Multicenter Study of Volumetric Computed Tomography for Staging Malignant Pleural Mesothelioma.
V. Rusch (2016)
Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database
V. Rusch (2012)
The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma
A. Nowak (2016)
Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma?
T. Frauenfelder (2011)
Imaging in pleural mesothelioma: a review of imaging research presented at the 9th International Meeting of the International Mesothelioma Interest Group.
A. Nowak (2010)
Summary of Prognostic Factors and Patient Selection for Extrapleural Pneumonectomy in the Treatment of Malignant Pleural Mesothelioma
Mbbs Christopher Cao BSc (2011)
Malignant mesothelioma: current status and perspective in Japan and the world
S. Hasegawa (2008)
Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma.
H. Pass (1998)
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
V. Rusch (1995)
The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: meeting summary of the International Mesothelioma Interest Group Congress, September 11-14, 2012, Boston, Mass.
V. Rusch (2013)
Extrapleural pneumonectomy and extended pleurectomy/decortication for malignant pleural mesothelioma: the Memorial Sloan-Kettering Cancer Center approach.
V. Rusch (2012)
Current surgical strategies for malignant pleural mesothelioma
T. Takuwa (2015)
Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies.
D. Sugarbaker (2004)
A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group.
V. Rusch (1996)
Current trends in radiologic management of malignant pleural mesothelioma.
R. Gill (2009)
North American Multicenter Volumetric CT Study for Clinical Staging of Malignant Pleural Mesothelioma: Feasibility and Logistics of Setting Up a Quantitative Imaging Study
R. Gill (2016)
A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma: A Review of 12 Years’ Experience
I. Opitz (2015)
Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis.
D. Nelson (2017)
Surgical assessment of malignant pleural mesothelioma: have we reached a critical stage?
A. Nakas (2010)
Prospective registry database of patients with malignant mesothelioma: directions for a future Japanese registry-based lung cancer study.
Y. Shintani (2018)
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)

This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar